Showing 1086 results
-
Press release /Chiffre d'affaires net de l'exercice 2016 (0% tcc[2]) comparable à celui de l'exercice précédent, grâce à l'excellente performance des produits de croissance Cosentyx (USD 1,1 milliard) a…
-
Ad hoc release /Annonce événementielle au sens de l’art. 53 RC Le spin-off de Sandoz parachève la spécialisation d’Innovative Medicines dans les médicaments innovants le commentaire ci-dessous concerne les…
-
Press release /Patient-reported outcomes (PROs) from the Phase III NATALEE trial show that patients receiving adjuvant Kisqali plus endocrine therapy (ET) for up to three years maintained physical and social…
-
Press release /Entresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker…
-
Press release /Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when…
-
Press release /With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in…
-
Story /Novartis teams test combinations of targeted therapeutic agents to combat drug resistance in tumors.
-
Story /Novartis researchers are collaborating with tech startup PathAI to search for hidden information in pathology slides.
-
Story /Technology used to tag friends on social media could change the way drug discovery is done.